The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Open accessAbstract
An incomplete view of the mechanisms that drive metastasis, the primary cause of cancer-related death, has been a major barrier to development of effective therapeutics and prognostic diagnostics. Increasing evidence indicates that the interplay between microenvironment, genetic lesions, and cellular plasticity drives the metastatic cascade and resistance to therapies. Here, using melanoma as a model, we outline the diversity and trajectories of cell states during metastatic dissemination and therapy exposure, and highlight how understanding the magnitude and dynamics of nongenetic reprogramming in space and time at single-cell resolution can be exploited to develop therapeutic strategies that capitalize on nongenetic tumor evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–227 of 227
The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma
Phung, B., Cieśla, M., Sanna, A. M., Guzzi, N., Beneventi, G., Ngoc, P. C. T., Lauss, M., Cabrita, R., Cordero, E., Bosch, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.069 · Cited by 89
Ennen, M., Keime, C., Gambi, G., Kieny, A., Coassolo, S., Thibault-Carpentier, C., Margerin-Schaller, F., Davidson, G., Vagne, C., Lipsker, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0010 · Cited by 87
Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth
Ferguson, J., Smith, M. P., Zudaire, I., Wellbrock, C., & Arozarena, I. (2017) · Oncotarget · doi:10.18632/oncotarget.16514 · Cited by 86
MITF controls the TCA cycle to modulate the melanoma hypoxia response
Louphrasitthiphol, P., Ledaki, I., Chauhan, J. S., Falletta, P., Siddaway, R., Buffa, F. M., Mole, D. R., Soga, T., & Goding, C. R. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12802 · Cited by 83
Self-citationMapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq
Gerber, T., Willscher, E., Loeffler‐Wirth, H., Hopp, L., Schadendorf, D., Schartl, M., Anderegg, U., Camp, J. G., Treutlein, B., Binder, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13666 · Cited by 80
Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line
Xue, Z., Yan, H. M., Li, J., Liang, S., Cai, X., Chen, X., Wu, Q., Gao, L., Wu, K., Nie, Y., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23356 · Cited by 79
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 79
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 77
Harnessing Tumor Evolution to Circumvent Resistance
McNamara, K. L., & Curtis, C. N. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.007 · Cited by 77
Ott, P. A., Pavlick, A. C., Johnson, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.31892 · Cited by 75
BRN 2, a POU erful driver of melanoma phenotype switching and metastasis
Fane, M. E., Chhabra, Y., Smith, A. G., & Sturm, R. A. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12710 · Cited by 71
Estimating the activity of transcription factors by the effect on their target genes
Schacht, T., Oswald, M., Eils, R., Eichmüller, S. B., & König, R. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu446 · Cited by 69
ccmGDB: a database for cancer cell metabolism genes
Kim, P., Cheng, F., Zhao, J., & Zhao, Z. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1128 · Cited by 61
SMAD signaling promotes melanoma metastasis independently of phenotype switching
Tuncer, E., Calçada, R. R., Zingg, D., Varum, S., Cheng, P. F., Freiberger, S. N., Deng, C., Kleiter, I., Levesque, M. P., Dummer, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci94295 · Cited by 61
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
Rose, A. A. N., Annis, M. G., Frederick, D. T., Biondini, M., Dong, Z., Kwong, L. N., Chin, L., Keler, T., Hawthorne, T. R., Watson, I. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1192 · Cited by 59
Wilson, R. E., Dooley, T. P., & Hart, I. R. (1989) · PubMed · Cited by 56
Fufa, T., Harris, M. L., Watkins‐Chow, D. E., Levy, D. J., Gorkin, D. U., Gildea, D. E., Song, L., Safi, A., Crawford, G. E., Sviderskaya, E. V., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv267 · Cited by 55
Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma
Almeida, F. V., Douglass, S. M., Fane, M. E., & Weeraratna, A. T. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12736 · Cited by 52
Dugo, M., Nicolini, G., Tragni, G., Bersani, I., Tomassetti, A., Colonna, V., Vecchio, M. D., de Braud, F., Canevari, S., Anichini, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3007 · Cited by 48
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy
Emmons, M. F., Faião‐Flores, F., & Smalley, K. S. M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.06.014 · Cited by 41
SUZUKI, T. A., Osumi, N., & Wakamatsu, Y. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.05.492 · Cited by 31
Westermarck, J. K. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-738-9_2 · Cited by 28
Ruiz‐Vela, A., Aguilar-Gallardo, C., Martínez-Arroyo, A. M., Soriano‐Navarro, M., Ruiz, V., & Simón, C. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9253-7 · Cited by 28
Loeffler‐Wirth, H., Binder, H., Willscher, E., Gerber, T., & Kunz, M. (2018) · Biology · doi:10.3390/biology7020023 · Cited by 24
Lee, G., Shim, J., Cho, B., Jung, J., Lee, D.-S., & Oh, I. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0734-2 · Cited by 20
Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding
Lu, M. M., Muers, M. R., & Lü, X. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.41 · Cited by 18
Wouters, J., Atak, Z. K., Minnoye, L., Spanier, K. I., Waegeneer, M. D., González‐Blas, C. B., Mauduit, D., Davie, K., Hulselmans, G. J., Najem, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/715995 · Cited by 12
Self-citation
Cited by
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma
Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K. I., De Waegeneer, M., Bravo González-Blas, C., Mauduit, D., Davie, K., Hulselmans, G., Najem, A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0547-3 · Cited by 258
Self-citationA TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Self-citationBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Cross-species analysis of enhancer logic using deep learning
Minnoye, L., Taskiran, I. I., Mauduit, D., Fazio, M., Van Aerschot, L., Hulselmans, G., Christiaens, V., Makhzami, S., Seltenhammer, M., Karras, P., et al. (2020) · Genome Research · doi:10.1101/gr.260844.120 · Cited by 116
Self-citation
Metadata
- Authors
- Rambow, F., Marine, J.-C., & Goding, C. R.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2019-10-01
- Volume
- 33
- Issue
- 19-20
- Pages
- 1295-1318
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2978972173
- Cited by
- 325
- References
- 227
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.